FAME-04: A Phase 1 trial to assess the safety, acceptability, pharmacokinetics and pharmacodynamics of film and gel formulations of tenofovir

Katherine E. Bunge, Charlene S. Dezzutti, Craig Hendrix, Mark A Marzinke, Hans M.L. Spiegel, Bernard J. Moncla, Jill L. Schwartz, Leslie A. Meyn, Nicola Richardson-Harman, Lisa C. Rohan, Sharon L. Hillier

Research output: Contribution to journalArticle

Abstract

Introduction: Fast-dissolving vaginal film formulations release antiretroviral drugs directly into vaginal fluid and may be as efficient at drug delivery yet more acceptable to women than gels. In this Phase 1 vaginal film study, the safety, acceptability, pharmacokinetics and pharmacodynamics of two doses of tenofovir (TFV) film and TFV 1% gel were compared to corresponding placebo formulations. Methods: Seventy-eight healthy HIV negative women were randomized to self-insert daily vaginal film (10 mg TFV, 40 mg TFV or placebo) or 4 mL of vaginal gel (TFV 1% [40 mg] or placebo) for seven days. Grade 2 and higher adverse events (AEs) related to study product were compared across study arms using Fisher's exact test. Plasma TFV concentrations were measured before and 2 hours after last product use. Paired cervical and vaginal tissue biopsies obtained 2 hours after the last dose were measured to determine tenofovir diphosphate (TFV-DP) concentrations and exposed to HIV in an ex vivo challenge assay. Acceptability was assessed through questionnaire. Results: There was only one grade 2 or higher related AE, the primary endpoint; it occurred in the placebo gel arm. AEs occurred in 90% of participants; the majority (91%) were grade 1. AEs were similar across study arms. TFV concentrations in plasma and TFV-DP concentrations in cervical and vaginal tissues were comparable between 40 mg TFV film and the TFV gel groups. There was a significant relationship between reduced viral replication and TFV-DP concentrations in cervical tissues. Film users were less likely to report product leakage than gel users (66% vs. 100%, p < 0.001). Conclusions: Films were safe and well tolerated. Furthermore, films delivered TFV to mucosal tissues at concentrations similar to gel and were sufficient to block HIV infection of genital tissue ex vivo.

Original languageEnglish (US)
Article numbere25156
JournalJournal of the International AIDS Society
Volume21
Issue number8
DOIs
StatePublished - Aug 1 2018

Fingerprint

Tenofovir
Pharmacokinetics
Gels
Safety
Placebos
HIV
Foams and Jellies Vaginal Creams

Keywords

  • microbicide
  • prevention
  • tenofovir
  • vaginal film
  • vaginal gel

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

FAME-04 : A Phase 1 trial to assess the safety, acceptability, pharmacokinetics and pharmacodynamics of film and gel formulations of tenofovir. / Bunge, Katherine E.; Dezzutti, Charlene S.; Hendrix, Craig; Marzinke, Mark A; Spiegel, Hans M.L.; Moncla, Bernard J.; Schwartz, Jill L.; Meyn, Leslie A.; Richardson-Harman, Nicola; Rohan, Lisa C.; Hillier, Sharon L.

In: Journal of the International AIDS Society, Vol. 21, No. 8, e25156, 01.08.2018.

Research output: Contribution to journalArticle

Bunge, Katherine E. ; Dezzutti, Charlene S. ; Hendrix, Craig ; Marzinke, Mark A ; Spiegel, Hans M.L. ; Moncla, Bernard J. ; Schwartz, Jill L. ; Meyn, Leslie A. ; Richardson-Harman, Nicola ; Rohan, Lisa C. ; Hillier, Sharon L. / FAME-04 : A Phase 1 trial to assess the safety, acceptability, pharmacokinetics and pharmacodynamics of film and gel formulations of tenofovir. In: Journal of the International AIDS Society. 2018 ; Vol. 21, No. 8.
@article{111a782d9fce4118bb5eb734728d5a35,
title = "FAME-04: A Phase 1 trial to assess the safety, acceptability, pharmacokinetics and pharmacodynamics of film and gel formulations of tenofovir",
abstract = "Introduction: Fast-dissolving vaginal film formulations release antiretroviral drugs directly into vaginal fluid and may be as efficient at drug delivery yet more acceptable to women than gels. In this Phase 1 vaginal film study, the safety, acceptability, pharmacokinetics and pharmacodynamics of two doses of tenofovir (TFV) film and TFV 1{\%} gel were compared to corresponding placebo formulations. Methods: Seventy-eight healthy HIV negative women were randomized to self-insert daily vaginal film (10 mg TFV, 40 mg TFV or placebo) or 4 mL of vaginal gel (TFV 1{\%} [40 mg] or placebo) for seven days. Grade 2 and higher adverse events (AEs) related to study product were compared across study arms using Fisher's exact test. Plasma TFV concentrations were measured before and 2 hours after last product use. Paired cervical and vaginal tissue biopsies obtained 2 hours after the last dose were measured to determine tenofovir diphosphate (TFV-DP) concentrations and exposed to HIV in an ex vivo challenge assay. Acceptability was assessed through questionnaire. Results: There was only one grade 2 or higher related AE, the primary endpoint; it occurred in the placebo gel arm. AEs occurred in 90{\%} of participants; the majority (91{\%}) were grade 1. AEs were similar across study arms. TFV concentrations in plasma and TFV-DP concentrations in cervical and vaginal tissues were comparable between 40 mg TFV film and the TFV gel groups. There was a significant relationship between reduced viral replication and TFV-DP concentrations in cervical tissues. Film users were less likely to report product leakage than gel users (66{\%} vs. 100{\%}, p < 0.001). Conclusions: Films were safe and well tolerated. Furthermore, films delivered TFV to mucosal tissues at concentrations similar to gel and were sufficient to block HIV infection of genital tissue ex vivo.",
keywords = "microbicide, prevention, tenofovir, vaginal film, vaginal gel",
author = "Bunge, {Katherine E.} and Dezzutti, {Charlene S.} and Craig Hendrix and Marzinke, {Mark A} and Spiegel, {Hans M.L.} and Moncla, {Bernard J.} and Schwartz, {Jill L.} and Meyn, {Leslie A.} and Nicola Richardson-Harman and Rohan, {Lisa C.} and Hillier, {Sharon L.}",
year = "2018",
month = "8",
day = "1",
doi = "10.1002/jia2.25156",
language = "English (US)",
volume = "21",
journal = "Journal of the International AIDS Society",
issn = "1758-2652",
publisher = "International AIDS Society",
number = "8",

}

TY - JOUR

T1 - FAME-04

T2 - A Phase 1 trial to assess the safety, acceptability, pharmacokinetics and pharmacodynamics of film and gel formulations of tenofovir

AU - Bunge, Katherine E.

AU - Dezzutti, Charlene S.

AU - Hendrix, Craig

AU - Marzinke, Mark A

AU - Spiegel, Hans M.L.

AU - Moncla, Bernard J.

AU - Schwartz, Jill L.

AU - Meyn, Leslie A.

AU - Richardson-Harman, Nicola

AU - Rohan, Lisa C.

AU - Hillier, Sharon L.

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Introduction: Fast-dissolving vaginal film formulations release antiretroviral drugs directly into vaginal fluid and may be as efficient at drug delivery yet more acceptable to women than gels. In this Phase 1 vaginal film study, the safety, acceptability, pharmacokinetics and pharmacodynamics of two doses of tenofovir (TFV) film and TFV 1% gel were compared to corresponding placebo formulations. Methods: Seventy-eight healthy HIV negative women were randomized to self-insert daily vaginal film (10 mg TFV, 40 mg TFV or placebo) or 4 mL of vaginal gel (TFV 1% [40 mg] or placebo) for seven days. Grade 2 and higher adverse events (AEs) related to study product were compared across study arms using Fisher's exact test. Plasma TFV concentrations were measured before and 2 hours after last product use. Paired cervical and vaginal tissue biopsies obtained 2 hours after the last dose were measured to determine tenofovir diphosphate (TFV-DP) concentrations and exposed to HIV in an ex vivo challenge assay. Acceptability was assessed through questionnaire. Results: There was only one grade 2 or higher related AE, the primary endpoint; it occurred in the placebo gel arm. AEs occurred in 90% of participants; the majority (91%) were grade 1. AEs were similar across study arms. TFV concentrations in plasma and TFV-DP concentrations in cervical and vaginal tissues were comparable between 40 mg TFV film and the TFV gel groups. There was a significant relationship between reduced viral replication and TFV-DP concentrations in cervical tissues. Film users were less likely to report product leakage than gel users (66% vs. 100%, p < 0.001). Conclusions: Films were safe and well tolerated. Furthermore, films delivered TFV to mucosal tissues at concentrations similar to gel and were sufficient to block HIV infection of genital tissue ex vivo.

AB - Introduction: Fast-dissolving vaginal film formulations release antiretroviral drugs directly into vaginal fluid and may be as efficient at drug delivery yet more acceptable to women than gels. In this Phase 1 vaginal film study, the safety, acceptability, pharmacokinetics and pharmacodynamics of two doses of tenofovir (TFV) film and TFV 1% gel were compared to corresponding placebo formulations. Methods: Seventy-eight healthy HIV negative women were randomized to self-insert daily vaginal film (10 mg TFV, 40 mg TFV or placebo) or 4 mL of vaginal gel (TFV 1% [40 mg] or placebo) for seven days. Grade 2 and higher adverse events (AEs) related to study product were compared across study arms using Fisher's exact test. Plasma TFV concentrations were measured before and 2 hours after last product use. Paired cervical and vaginal tissue biopsies obtained 2 hours after the last dose were measured to determine tenofovir diphosphate (TFV-DP) concentrations and exposed to HIV in an ex vivo challenge assay. Acceptability was assessed through questionnaire. Results: There was only one grade 2 or higher related AE, the primary endpoint; it occurred in the placebo gel arm. AEs occurred in 90% of participants; the majority (91%) were grade 1. AEs were similar across study arms. TFV concentrations in plasma and TFV-DP concentrations in cervical and vaginal tissues were comparable between 40 mg TFV film and the TFV gel groups. There was a significant relationship between reduced viral replication and TFV-DP concentrations in cervical tissues. Film users were less likely to report product leakage than gel users (66% vs. 100%, p < 0.001). Conclusions: Films were safe and well tolerated. Furthermore, films delivered TFV to mucosal tissues at concentrations similar to gel and were sufficient to block HIV infection of genital tissue ex vivo.

KW - microbicide

KW - prevention

KW - tenofovir

KW - vaginal film

KW - vaginal gel

UR - http://www.scopus.com/inward/record.url?scp=85053275786&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053275786&partnerID=8YFLogxK

U2 - 10.1002/jia2.25156

DO - 10.1002/jia2.25156

M3 - Article

C2 - 30101439

AN - SCOPUS:85053275786

VL - 21

JO - Journal of the International AIDS Society

JF - Journal of the International AIDS Society

SN - 1758-2652

IS - 8

M1 - e25156

ER -